바이오의약품 시장(2025-2035년)

The global Biologics market is projected to grow at a CAGR of 8.5% by 2035.

The Biologics Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Escalating Demand for Biologics is Boosting the Market Growth

The escalating demand for biologics continues to be a significant driver of growth in the pharmaceutical market as of 2025. Biologics-therapies derived from living organisms-are renowned for their precision in targeting specific molecules or cells, leading to effective treatments with reduced side effects. This precision makes them particularly valuable in addressing complex medical conditions such as cancer, autoimmune disorders, and rare genetic diseases.

What Questions Should You Ask before Buying a Market Research Report?

• How is the biologics market evolving?
• What is driving and restraining the biologics market?
• How will each biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each biologics submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading biologics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biologics projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of biologics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the biologics market?
• Where is the biologics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biologics market today, and over the next 10 years:

• Our 367-page report provides 136 tables and 228 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them - NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2035 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biologics prices and recent developments.

Segments Covered in the Report

• Product
• Monoclonal Antibodies
• Human
• Humanized
• Chimeric
• Murine
• Vaccines
• Recombinant Proteins
• Regenerative Medicine
• Tissue Engineered Products
• Cell Therapy
• Gene Therapies
• Others
• Application
• Oncology
• Infectious Diseases
• Autoimmune Disease
• Haematological Disorder
• Cardiovascular Disorders
• Others
• Manufacturing Type
• Outsource
• In-house
• Source
• Mammalian
• Microbial
• Others
• End-users
• Hospitals
• Speciality Centres
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America
• MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Biologics Market, 2025 to 2035, with a focus on this segment of these companies' operations.

• Leading companies and the potential for market growth
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Johnson & Johnson
• Merck & Co.
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi

Overall world revenue for Biologics Market, 2025 to 2035 in terms of value the market will surpass US$450.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Biologics Market, 2025 to 2035 report help you?
• In summary, our 360+ page report provides you with the following knowledge:
• Revenue forecasts to 2035 for Biologics Market, 2025 to 2035, with forecasts for product, application, manufacturing type, source, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 24 key national markets - See forecasts for the Biologics Market, 2025 to 2035 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Biologics Market, 2025 to 2035.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Biologics Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Rising Demand for Biologics
    • 3.3.1.2 Advancements in Biomedical Science
    • 3.3.1.3 Rising Investments in Biopharmaceutical R&D
    • 3.3.1.4 Rising Prevalence of Chronic Diseases
    • 3.3.1.5 Increase in Number of Elderly Population will Drive the Market Growth
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 High Production Costs
    • 3.3.2.2 Navigating Immunogenicity and Adverse Reactions in Biologics Development
    • 3.3.2.3 High Stringency and Low Turnover for Clinical Trials
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Mergers, Acquisitions, and Collaborations in Biologics
    • 3.3.3.2 Surging Drug Approvals and Launches of Biologics
    • 3.3.3.3 Increasing Outsourcing of Biopharmaceutical Activities to CROs
    • 3.3.3.4 Emerging Economies Expansion and Prioritisation of R&D
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Supplier Power
  • 3.4.2 Buyer Power
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis
• 3.6 The Rise of Biologics in Modern Medicine
  • 3.6.1 Navigating New Frontiers in GI Disease Treatment
  • 3.6.2 Transforming Food Allergy Treatment
  • 3.6.3 Challenges in Biologics: Production and Delivery
  • 3.6.4 The Future Looks Bright
  • 3.6.5 Precision Medicine: The Next Frontier
  • 3.6.6 Advancing Drug Delivery Techniques
  • 3.6.7 Navigating the Future of Biologics with Optimism and Awareness
• 3.7 Navigating the Biologics Manufacturing Lifecycle: From Preclinical to Clinical
  • 3.7.1 The Journey from Preclinical Development to Clinical Manufacturing in Biologics
  • 3.7.2 What Does the Biologics Journey from Preclinical Development to Clinical Manufacturing Look Like?
  • 3.7.3 Key Challenges in the Transition from Preclinical Development to Clinical Manufacturing
  • 3.7.4 Innovations and Emerging Trends Shaping Biologics Manufacturing
  • 3.7.5 Advice for Teams Embarking on Biologics Development

4 Biologics Market Analysis by Product

• 4.1 Key Findings
• 4.2 Product Segment: Market Attractiveness Index
• 4.3 Biologics Market Size Estimation and Forecast by Product
• 4.4 Monoclonal Antibodies
  • 4.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.4.2 Market Share by Region, 2025 & 2035 (%)
  • 4.4.3 Human
    • 4.4.3.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.3.2 Market Share by Region, 2024 & 2034 (%)
  • 4.4.4 Humanized
    • 4.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.4.5 Chimeric
    • 4.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.4.6 Murine
    • 4.4.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.6.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Vaccines
  • 4.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.5.2 Market Share by Region, 2025 & 2035 (%)
• 4.6 Recombinant Proteins
  • 4.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.6.2 Market Share by Region, 2025 & 2035 (%)
• 4.7 Regenerative Medicine
  • 4.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.7.2 Market Share by Region, 2025 & 2035 (%)
  • 4.7.3 Tissue Engineered Products
    • 4.7.3.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.7.3.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7.4 Cell Therapy
    • 4.7.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7.5 Gene Therapies
    • 4.7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.7.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.8 Others
  • 4.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.8.2 Market Share by Region, 2025 & 2035 (%)

5 Biologics Market Analysis by Source

• 5.1 Key Findings
• 5.2 Source Segment: Market Attractiveness Index
• 5.3 Biologics Market Size Estimation and Forecast by Source
• 5.4 Mammalian
  • 5.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.4.2 Market Share by Region, 2025 & 2035 (%)
• 5.5 Microbial
  • 5.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.5.2 Market Share by Region, 2025 & 2035 (%)
• 5.6 Others
  • 5.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.6.2 Market Share by Region, 2025 & 2035 (%)

6 Biologics Market Analysis by Application

• 6.1 Key Findings
• 6.2 Application Segment: Market Attractiveness Index
• 6.3 Biologics Market Size Estimation and Forecast by Application
• 6.4 Oncology
  • 6.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.4.2 Market Share by Region, 2025 & 2035 (%)
• 6.5 Infectious Diseases
  • 6.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.5.2 Market Share by Region, 2025 & 2035 (%)
• 6.6 Autoimmune Disease
  • 6.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.6.2 Market Share by Region, 2025 & 2035 (%)
• 6.7 Haematological Disorder
  • 6.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.7.2 Market Share by Region, 2025 & 2035 (%)
• 6.8 Cardiovascular Disorders
  • 6.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.8.2 Market Share by Region, 2025 & 2035 (%)
• 6.9 Others
  • 6.9.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.9.2 Market Share by Region, 2025 & 2035 (%)

7 Biologics Market Analysis by Manufacturing Type

• 7.1 Key Findings
• 7.2 Manufacturing Type Segment: Market Attractiveness Index
• 7.3 Biologics Market Size Estimation and Forecast by Manufacturing Type
• 7.4 Outsource
  • 7.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.4.2 Market Share by Region, 2025 & 2035 (%)
• 7.5 In-house
  • 7.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.5.2 Market Share by Region, 2025 & 2035 (%)

8 Biologics Market Analysis by End-users

• 8.1 Key Findings
• 8.2 End-users Segment: Market Attractiveness Index
• 8.3 Biologics Market Size Estimation and Forecast by End-users
• 8.4 Hospitals
  • 8.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 8.4.2 Market Share by Region, 2025 & 2035 (%)
• 8.5 Speciality Centres
  • 8.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 8.5.2 Market Share by Region, 2025 & 2035 (%)
• 8.6 Others
  • 8.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 8.6.2 Market Share by Region, 2025 & 2035 (%)

9 Biologics Market Analysis by Region

• 9.1 Key Findings
• 9.2 Regional Market Size Estimation and Forecast

10 North America Biologics Market Analysis

• 10.1 Key Findings
• 10.2 North America Biologics Market Attractiveness Index
• 10.3 North America Biologics Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 10.4 North America Biologics Market Size Estimation and Forecast by Country
• 10.5 North America Biologics Market Size Estimation and Forecast by Product
• 10.6 North America Biologics Market Size Estimation and Forecast by Source
• 10.7 North America Biologics Market Size Estimation and Forecast by Application
• 10.8 North America Biologics Market Size Estimation and Forecast by Manufacturing Type
• 10.9 North America Biologics Market Size Estimation and Forecast by End-users
• 10.10 U.S. Biologics Market Analysis
• 10.11 Canada Biologics Market Analysis

11 Europe Biologics Market Analysis

• 11.1 Key Findings
• 11.2 Europe Biologics Market Attractiveness Index
• 11.3 Europe Biologics Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 11.4 Europe Biologics Market Size Estimation and Forecast by Country
• 11.5 Europe Biologics Market Size Estimation and Forecast by Product
• 11.6 Europe Biologics Market Size Estimation and Forecast by Source
• 11.7 Europe Biologics Market Size Estimation and Forecast by Application
• 11.8 Europe Biologics Market Size Estimation and Forecast by Manufacturing Type
• 11.9 Europe Biologics Market Size Estimation and Forecast by End-users
• 11.10 Germany Biologics Market Analysis
• 11.11 UK Biologics Market Analysis
• 11.12 France Biologics Market Analysis
• 11.13 Italy Biologics Market Analysis
• 11.14 Spain Biologics Market Analysis
• 11.15 Russia Biologics Market Analysis
• 11.16 Rest of Europe Biologics Market Analysis

12 Asia Pacific Biologics Market Analysis

• 12.1 Key Findings
• 12.2 Asia Pacific Biologics Market Attractiveness Index
• 12.3 Asia Pacific Biologics Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 12.4 Asia Pacific Biologics Market Size Estimation and Forecast by Country
• 12.5 Asia Pacific Biologics Market Size Estimation and Forecast by Product
• 12.6 Asia Pacific Biologics Market Size Estimation and Forecast by Source
• 12.7 Asia Pacific Biologics Market Size Estimation and Forecast by Application
• 12.8 Asia Pacific Biologics Market Size Estimation and Forecast by Manufacturing Type
• 12.9 Asia Pacific Biologics Market Size Estimation and Forecast by End-users
• 12.10 Japan Biologics Market Analysis
• 12.11 China Biologics Market Analysis
• 12.12 India Biologics Market Analysis
• 12.13 Australia Biologics Market Analysis
• 12.14 South Korea Biologics Market Analysis
• 12.15 South-East Asia Biologics Market Analysis
• 12.16 Rest of Asia Pacific Biologics Market Analysis

13 Latin America Biologics Market Analysis

• 13.1 Key Findings
• 13.2 Latin America Biologics Market Attractiveness Index
• 13.3 Latin America Biologics Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 13.4 Latin America Biologics Market Size Estimation and Forecast by Country
• 13.5 Latin America Biologics Market Size Estimation and Forecast by Product
• 13.6 Latin America Biologics Market Size Estimation and Forecast by Source
• 13.7 Latin America Biologics Market Size Estimation and Forecast by Application
• 13.8 Latin America Biologics Market Size Estimation and Forecast by Manufacturing Type
• 13.9 Latin America Biologics Market Size Estimation and Forecast by End-users
• 13.10 Brazil Biologics Market Analysis
• 13.11 Mexico Biologics Market Analysis
• 13.12 Argentina Biologics Market Analysis
• 13.13 Colombia Biologics Market Analysis
• 13.14 Rest of Latin America Biologics Market Analysis

14 MEA Biologics Market Analysis

• 14.1 Key Findings
• 14.2 MEA Biologics Market Attractiveness Index
• 14.3 MEA Biologics Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 14.4 MEA Biologics Market Size Estimation and Forecast by Country
• 14.5 MEA Biologics Market Size Estimation and Forecast by Product
• 14.6 MEA Biologics Market Size Estimation and Forecast by Source
• 14.7 MEA Biologics Market Size Estimation and Forecast by Application
• 14.8 MEA Biologics Market Size Estimation and Forecast by Manufacturing Type
• 14.9 MEA Biologics Market Size Estimation and Forecast by End-users
• 14.10 GCC Biologics Market Analysis
• 14.11 South Africa Biologics Market Analysis
• 14.12 Rest of MEA Biologics Market Analysis

15 Company Profiles

• 15.1 Competitive Landscape
• 15.2 Johnson & Johnson
  • 15.2.1 Company Snapshot
  • 15.2.2 Company Overview
  • 15.2.3 Financial Analysis
    • 15.2.3.1 Net Revenue,2019-2024
    • 15.2.3.2 R&D,2019-2024
    • 15.2.3.3 Regional Market Shares, 2024
    • 15.2.3.4 Business Market Shares, 2024
  • 15.2.4 Product Benchmarking
  • 15.2.5 Strategic Outlook
• 15.3 F. Hoffmann-La Roche AG
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Financial Analysis
    • 15.3.3.1 Net Revenue, 2019-2024
    • 15.3.3.2 R&D, 2019-2024
    • 15.3.3.3 Business Market Shares, 2024
  • 15.3.4 Product Benchmarking
  • 15.3.5 Strategic Outlook
• 15.4 Amgen Inc.
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Financial Analysis
    • 15.4.3.1 Net Revenue, 2019-2024
    • 15.4.3.2 R&D, 2019-2024
    • 15.4.3.3 Regional Market Shares, 2024
    • 15.4.3.4 Business Market Shares, 2024
  • 15.4.4 Product Benchmarking
  • 15.4.5 Strategic Outlook
• 15.5 AbbVie Inc.
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Financial Analysis
    • 15.5.3.1 Net Revenue, 2019-2024
    • 15.5.3.2 R&D, 2019-2024
    • 15.5.3.3 Regional Market Shares, 2024
    • 15.5.3.4 Business Market Shares, 2024
  • 15.5.4 Product Benchmarking
  • 15.5.5 Strategic Outlook
• 15.6 Novo Nordisk A/S
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Financial Analysis
    • 15.6.3.1 Net Revenue, 2019-2024
    • 15.6.3.2 R&D, 2019-2024
    • 15.6.3.3 Regional Market Shares, 2024
    • 15.6.3.4 Business Market Shares, 2024
  • 15.6.4 Product Benchmarking
  • 15.6.5 Strategic Outlook
• 15.7 Eli Lilly and Company
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Financial Analysis
    • 15.7.3.1 Net Revenue, 2019-2024
    • 15.7.3.2 R&D, 2019-2024
    • 15.7.3.3 Regional Market Shares, 2024
  • 15.7.4 Product Benchmarking
  • 15.7.5 Strategic Outlook
• 15.8 Bristol-Myers Squibb Company
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Financial Analysis
    • 15.8.3.1 Net Revenue, 2019-2024
    • 15.8.3.2 R&D, 2019-2024
    • 15.8.3.3 Regional Market Shares, 2024
  • 15.8.4 Product Benchmarking
  • 15.8.5 Strategic Outlook
• 15.9 Merck & Co.
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Financial Analysis
    • 15.9.3.1 Net Revenue, 2019-2024
    • 15.9.3.2 R&D, 2019-2024
    • 15.9.3.3 Regional Market Shares, 2024
    • 15.9.3.4 Business Market Shares, 2024
  • 15.9.4 Product Benchmarking
  • 15.9.5 Strategic Outlook
• 15.10 AstraZeneca plc
  • 15.10.1 Company Snapshot
  • 15.10.2 Company Overview
  • 15.10.3 Financial Analysis
    • 15.10.3.1 Net Revenue, 2019-2024
    • 15.10.3.2 R&D, 2019-2024
    • 15.10.3.3 Regional Market Shares, 2024
  • 15.10.4 Product Benchmarking
  • 15.10.5 Strategic Outlook
• 15.11 Sanofi
  • 15.11.1 Company Snapshot
  • 15.11.2 Company Overview
  • 15.11.3 Financial Analysis
    • 15.11.3.1 Net Revenue, 2019-2024
    • 15.11.3.2 R&D, 2019-2024
    • 15.11.3.3 Regional Market Shares, 2024
  • 15.11.4 Product Benchmarking
  • 15.11.5 Strategic Outlook
• 15.12 Pfizer Inc.
  • 15.12.1 Company Snapshot
  • 15.12.2 Company Overview
  • 15.12.3 Financial Analysis
    • 15.12.3.1 Net Revenue, 2019-2024
    • 15.12.3.2 R&D, 2019-2024
    • 15.12.3.3 Regional Market Shares, 2024
    • 15.12.3.4 Business Market Shares, 2024
  • 15.12.4 Product Benchmarking
  • 15.12.5 Strategic Outlook
• 15.13 Regeneron Pharmaceuticals, Inc.
  • 15.13.1 Company Snapshot
  • 15.13.2 Company Overview
  • 15.13.3 Financial Analysis
    • 15.13.3.1 Net Revenue,2019-2024
    • 15.13.3.2 R&D,2019-2024
  • 15.13.4 Product Benchmarking
  • 15.13.5 Strategic Outlook
• 15.14 Gilead Sciences, Inc.
  • 15.14.1 Company Snapshot
  • 15.14.2 Company Overview
  • 15.14.3 Financial Analysis
    • 15.14.3.1 Net Revenue,2019-2024
    • 15.14.3.2 R&D,2019-2024
    • 15.14.3.3 Regional Market Shares, 2024
    • 15.14.3.4 Business Market Shares, 2024
  • 15.14.4 Product Benchmarking
  • 15.14.5 Strategic Outlook
• 15.15 Celltrion, Inc.
  • 15.15.1 Company Snapshot
  • 15.15.2 Company Overview
  • 15.15.3 Product Benchmarking
  • 15.15.4 Strategic Outlook
• 15.16 Biogen Inc.
  • 15.16.1 Company Snapshot
  • 15.16.2 Company Overview
  • 15.16.3 Financial Analysis
    • 15.16.3.1 Net Revenue, 2019-2024
    • 15.16.3.2 R&D, 2019-2024
    • 15.16.3.3 Regional Market Shares, 2024
  • 15.16.4 Product Benchmarking
  • 15.16.5 Strategic Outlook
• 15.17 GSK plc
  • 15.17.1 Company Snapshot
  • 15.17.2 Company Overview
  • 15.17.3 Financial Analysis
    • 15.17.3.1 Net Revenue,2019-2024
    • 15.17.3.2 R&D,2019-2024
    • 15.17.3.3 Regional Market Shares, 2024
    • 15.17.3.4 Business Market Shares, 2024
  • 15.17.4 Product Benchmarking
  • 15.17.5 Strategic Outlook

16 Conclusion and Recommendations

• 16.1 Concluding Remarks from Visiongain
• 16.2 Recommendations for Market Players